Protocol Ledger

NCT04573023 · Phase III · ACTIVE NOT RECRUITING

A Phase III Study of JR-141 in Patients With Mucopolysaccharidosis II (STARLIGHT)

Interventional Phase III clinical trial protocol NCT04573023 sponsored by JCR Pharmaceuticals Co in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-02-14 Enrollment: 86 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04573023
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)86 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04573023
Protocol FieldVerified Registry Value
NCT IdentifierNCT04573023
Consolidated Lead SponsorJCR Pharmaceuticals Co
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment86 participants (ACTUAL)
Registered Start Date2022-02-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI